Ovarian Cancer Clinical Trials in Dallas

Showing 41-60 of 189 trials

Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer

NCT03622385

The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.

Epithelial Ovarian Cancer

Baylor Research Institute10 participantsStarted Feb 2019

Dallas, Texas, United States

RECRUITINGPhase 1/2< 1 mile

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Colorectal CancerCholangiocarcinomaAppendiceal Adenocarcinoma+6 more

Apollo Therapeutics Ltd100 participantsStarted Jun 2024

Duarte, California, United States • Irvine, California, United States • Sarasota, Florida, United States +6 more locations

Active Not RecruitingPhase 3< 1 mile

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more

AstraZeneca450 participantsStarted Aug 2013

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Phoenix, Arizona, United States +174 more locations

Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Ovarian Cancer Trials in Other Cities

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

A Study of XMT-1660 in Participants With Solid Tumors

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Nirogacestat in Ovarian Granulosa Cell Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

A Study of PHN-010 in Patients With Advanced Solid Tumors

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

A Study of PF-06873600 in People With Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

EXoPERT EMERALD Clinical Study

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Other Conditions in Dallas